Search

Author/Creator Pang, Wuyan

2. Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open‐label, randomized controlled trial (BEYOND VII). Issue 5 (18th February 2020)

Authors:
Ji, Linong; Wan, Hailong; Wen, Binhong; Wang, Xueying; Wang, Junfen; Bian, Rongwen; Pang, Wuyan; Tian, Jian; Wang, Yan; Bian, Fang; Gao, Zhengnan; Condoleon, Alex; Feng, Wei; Zhang, Xia; Cui, Nan
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 22:Issue 5(2020)
Page Start:
838
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial. Issue 11 (25th July 2022)

Authors:
Yuan, Xiaoyong; Guo, Xiaohui; Zhang, Junqing; Dong, Xiaolin; Lu, Yibing; Pang, Wuyan; Gu, Shenghong; Niemoeller, Elisabeth; Ping, Lin; Nian, Gaowei; Souhami, Elisabeth
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 24:Issue 11(2022)
Page Start:
2182
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search